Role of telavancin in treatment of skin and skin structure infections

Skin and skin structure infections (SSSIs) are a common diagnosis encountered by ambulatory and inpatient practitioners across the country. As the SSSIs become more complicated, they require increased health care resources and often involve hospitalization and intravenous antimicrobials. Complicated...

Full description

Saved in:
Bibliographic Details
Published in:Clinical, cosmetic and investigational dermatology cosmetic and investigational dermatology, 2010-10, Vol.3 (default), p.127-133
Main Authors: Bonkowski, Joseph, Daniels, Anne R, Peppard, William J
Format: Article
Language:English
Subjects:
Antibiotics
Antimicrobial agents
Review
Staphylococcus infections
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c401t-fd80388a420de24bfaa0317b8ef2f941532f3ee0e98dc953c436d3a73f81e67a3
cites
container_end_page 133
container_issue default
container_start_page 127
container_title Clinical, cosmetic and investigational dermatology
container_volume 3
creator Bonkowski, Joseph
Daniels, Anne R
Peppard, William J
description Skin and skin structure infections (SSSIs) are a common diagnosis encountered by ambulatory and inpatient practitioners across the country. As the SSSIs become more complicated, they require increased health care resources and often involve hospitalization and intravenous antimicrobials. Complicated SSSIs are caused by a variety of pathogens, including Gram-positive, Gram-negative, and anerobic bacteria. Empiric broad-spectrum antibiotic coverage is warranted, taking into account area disease-state epidemiology and antimicrobial susceptibility data. Telavancin is an antimicrobial agent with a broad Gram-positive spectrum of activity which was recently approved for the treatment of SSSIs. It may especially benefit patients with resistant organisms, such as methicillin-resistant Staphylococcus aureus. This article reviews telavancin and its pharmacology, efficacy, and safety data to enhance the practitioner's knowledge base on the appropriateness of telavancin for the treatment of SSSIs.
doi_str_mv 10.2147/CCID.S9027
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_4ee36a23b6ca48fcbedd146298f7b6b0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_4ee36a23b6ca48fcbedd146298f7b6b0</doaj_id><sourcerecordid>2222235840</sourcerecordid><originalsourceid>FETCH-LOGICAL-c401t-fd80388a420de24bfaa0317b8ef2f941532f3ee0e98dc953c436d3a73f81e67a3</originalsourceid><addsrcrecordid>eNpdkVFrFDEQx4MobTn70g8gBz4IwtUkk91kXwS51npQEFp9DrPZSd1zb1OTbMFvb7bXltYhkGHmnx8z-TN2IvipFEp_Wq83Z6fXDZf6FTsSQpuV5qJ6_Sw_ZMcpbXkJaCoN5oAdlpegea2P2PlVGGgZ_DLTgHc4un5clpMjYd7RmOdW-l0qOHb7JOU4uTxFKjpPLvdhTG_ZG49DouOHe8F-fj3_sf62uvx-sVl_uVw5xUVe-c5wMAaV5B1J1XpEDkK3hrz0jRIVSA9EnBrTuaYCp6DuADV4I6jWCAu22XO7gFt7G_sdxr82YG_vCyHeWIy5dwNZRQQ1Smhrh8p411LXCVXLxnjd1i0vrM971u3U7qhzZdmIwwvoy87Y_7I34c4CV7pRUAAfHgAx_JkoZbvrk6NhwJHClKypjDZclT0W7P1_ym2Y4lh-yso5oDJqHujjXuViSCmSf5pFcDt7bWev7b3XRfzu-fRP0kdn4R977qRW</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2222235840</pqid></control><display><type>article</type><title>Role of telavancin in treatment of skin and skin structure infections</title><source>Taylor &amp; Francis Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Bonkowski, Joseph ; Daniels, Anne R ; Peppard, William J</creator><creatorcontrib>Bonkowski, Joseph ; Daniels, Anne R ; Peppard, William J</creatorcontrib><description>Skin and skin structure infections (SSSIs) are a common diagnosis encountered by ambulatory and inpatient practitioners across the country. As the SSSIs become more complicated, they require increased health care resources and often involve hospitalization and intravenous antimicrobials. Complicated SSSIs are caused by a variety of pathogens, including Gram-positive, Gram-negative, and anerobic bacteria. Empiric broad-spectrum antibiotic coverage is warranted, taking into account area disease-state epidemiology and antimicrobial susceptibility data. Telavancin is an antimicrobial agent with a broad Gram-positive spectrum of activity which was recently approved for the treatment of SSSIs. It may especially benefit patients with resistant organisms, such as methicillin-resistant Staphylococcus aureus. This article reviews telavancin and its pharmacology, efficacy, and safety data to enhance the practitioner's knowledge base on the appropriateness of telavancin for the treatment of SSSIs.</description><identifier>ISSN: 1178-7015</identifier><identifier>EISSN: 1178-7015</identifier><identifier>DOI: 10.2147/CCID.S9027</identifier><identifier>PMID: 21437067</identifier><language>eng</language><publisher>New Zealand: Taylor &amp; Francis Ltd</publisher><subject>Antibiotics ; Antimicrobial agents ; Review ; Staphylococcus infections</subject><ispartof>Clinical, cosmetic and investigational dermatology, 2010-10, Vol.3 (default), p.127-133</ispartof><rights>2010. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2010 Bonkowski et al, publisher and licensee Dove Medical Press Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c401t-fd80388a420de24bfaa0317b8ef2f941532f3ee0e98dc953c436d3a73f81e67a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2222235840/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2222235840?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21437067$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bonkowski, Joseph</creatorcontrib><creatorcontrib>Daniels, Anne R</creatorcontrib><creatorcontrib>Peppard, William J</creatorcontrib><title>Role of telavancin in treatment of skin and skin structure infections</title><title>Clinical, cosmetic and investigational dermatology</title><addtitle>Clin Cosmet Investig Dermatol</addtitle><description>Skin and skin structure infections (SSSIs) are a common diagnosis encountered by ambulatory and inpatient practitioners across the country. As the SSSIs become more complicated, they require increased health care resources and often involve hospitalization and intravenous antimicrobials. Complicated SSSIs are caused by a variety of pathogens, including Gram-positive, Gram-negative, and anerobic bacteria. Empiric broad-spectrum antibiotic coverage is warranted, taking into account area disease-state epidemiology and antimicrobial susceptibility data. Telavancin is an antimicrobial agent with a broad Gram-positive spectrum of activity which was recently approved for the treatment of SSSIs. It may especially benefit patients with resistant organisms, such as methicillin-resistant Staphylococcus aureus. This article reviews telavancin and its pharmacology, efficacy, and safety data to enhance the practitioner's knowledge base on the appropriateness of telavancin for the treatment of SSSIs.</description><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Review</subject><subject>Staphylococcus infections</subject><issn>1178-7015</issn><issn>1178-7015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkVFrFDEQx4MobTn70g8gBz4IwtUkk91kXwS51npQEFp9DrPZSd1zb1OTbMFvb7bXltYhkGHmnx8z-TN2IvipFEp_Wq83Z6fXDZf6FTsSQpuV5qJ6_Sw_ZMcpbXkJaCoN5oAdlpegea2P2PlVGGgZ_DLTgHc4un5clpMjYd7RmOdW-l0qOHb7JOU4uTxFKjpPLvdhTG_ZG49DouOHe8F-fj3_sf62uvx-sVl_uVw5xUVe-c5wMAaV5B1J1XpEDkK3hrz0jRIVSA9EnBrTuaYCp6DuADV4I6jWCAu22XO7gFt7G_sdxr82YG_vCyHeWIy5dwNZRQQ1Smhrh8p411LXCVXLxnjd1i0vrM971u3U7qhzZdmIwwvoy87Y_7I34c4CV7pRUAAfHgAx_JkoZbvrk6NhwJHClKypjDZclT0W7P1_ym2Y4lh-yso5oDJqHujjXuViSCmSf5pFcDt7bWev7b3XRfzu-fRP0kdn4R977qRW</recordid><startdate>20101007</startdate><enddate>20101007</enddate><creator>Bonkowski, Joseph</creator><creator>Daniels, Anne R</creator><creator>Peppard, William J</creator><general>Taylor &amp; Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>KB0</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20101007</creationdate><title>Role of telavancin in treatment of skin and skin structure infections</title><author>Bonkowski, Joseph ; Daniels, Anne R ; Peppard, William J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c401t-fd80388a420de24bfaa0317b8ef2f941532f3ee0e98dc953c436d3a73f81e67a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Review</topic><topic>Staphylococcus infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bonkowski, Joseph</creatorcontrib><creatorcontrib>Daniels, Anne R</creatorcontrib><creatorcontrib>Peppard, William J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database (ProQuest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Clinical, cosmetic and investigational dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bonkowski, Joseph</au><au>Daniels, Anne R</au><au>Peppard, William J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of telavancin in treatment of skin and skin structure infections</atitle><jtitle>Clinical, cosmetic and investigational dermatology</jtitle><addtitle>Clin Cosmet Investig Dermatol</addtitle><date>2010-10-07</date><risdate>2010</risdate><volume>3</volume><issue>default</issue><spage>127</spage><epage>133</epage><pages>127-133</pages><issn>1178-7015</issn><eissn>1178-7015</eissn><abstract>Skin and skin structure infections (SSSIs) are a common diagnosis encountered by ambulatory and inpatient practitioners across the country. As the SSSIs become more complicated, they require increased health care resources and often involve hospitalization and intravenous antimicrobials. Complicated SSSIs are caused by a variety of pathogens, including Gram-positive, Gram-negative, and anerobic bacteria. Empiric broad-spectrum antibiotic coverage is warranted, taking into account area disease-state epidemiology and antimicrobial susceptibility data. Telavancin is an antimicrobial agent with a broad Gram-positive spectrum of activity which was recently approved for the treatment of SSSIs. It may especially benefit patients with resistant organisms, such as methicillin-resistant Staphylococcus aureus. This article reviews telavancin and its pharmacology, efficacy, and safety data to enhance the practitioner's knowledge base on the appropriateness of telavancin for the treatment of SSSIs.</abstract><cop>New Zealand</cop><pub>Taylor &amp; Francis Ltd</pub><pmid>21437067</pmid><doi>10.2147/CCID.S9027</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-7015
ispartof Clinical, cosmetic and investigational dermatology, 2010-10, Vol.3 (default), p.127-133
issn 1178-7015
1178-7015
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_4ee36a23b6ca48fcbedd146298f7b6b0
source Taylor & Francis Open Access; Publicly Available Content Database; PubMed Central
subjects Antibiotics
Antimicrobial agents
Review
Staphylococcus infections
title Role of telavancin in treatment of skin and skin structure infections
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T18%3A06%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20telavancin%20in%20treatment%20of%20skin%20and%20skin%20structure%20infections&rft.jtitle=Clinical,%20cosmetic%20and%20investigational%20dermatology&rft.au=Bonkowski,%20Joseph&rft.date=2010-10-07&rft.volume=3&rft.issue=default&rft.spage=127&rft.epage=133&rft.pages=127-133&rft.issn=1178-7015&rft.eissn=1178-7015&rft_id=info:doi/10.2147/CCID.S9027&rft_dat=%3Cproquest_doaj_%3E2222235840%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c401t-fd80388a420de24bfaa0317b8ef2f941532f3ee0e98dc953c436d3a73f81e67a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2222235840&rft_id=info:pmid/21437067&rfr_iscdi=true